Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.

Eli Lilly just dropped $1 billion—plus a $300 million bonus if trials go well—on gene therapy firm Verve, aiming to spice up ...

On the sidelines of BIO2025, Julie Gilmore, head of Lilly Gateway Labs, shares her thoughts on the $1.3 billion Verve Therapeutics buy, where Lilly’s therapeutic puck is potentially going and how the ...

Wall Street remained steady as investors awaited the Federal Reserve's policy decision, while global markets reacted to ...

U.S. stocks are holding nearly in place as Wall Street waits to hear where the Federal Reserve may be taking interest rates.

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...

Breyers ice cream has been recalled due to mislabeling, Wendy's is partnering with Takis Fuego to offer a spicy chicken ...

ITW sees steady growth in key segments and margins, but debt concerns and weakness in the MTS Test & Simulation unit cloud the outlook.

Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for about $1 billion upfront. The deal gives ...

Verve Therapeutics remains an early-stage biotech, making the rally purely acquisition-driven, not based on fundamentals.

Eli Lilly has announced that it will be acquiring Verve Therapeutics in a deal worth approximately $1.3bn, marking a ...

Eli Lilly has agreed to acquire cardiovascular disease treatment specialist Verve Therapeutics in a deal potentially rising ...